Sharfstein Takes “Acting” Title Literally, Starting FDA Overhaul
This article was originally published in The Tan Sheet
Executive Summary
Before his first week on the job was over, FDA Acting Commissioner Josh Sharfstein made decisive moves on two fronts, quickly stepping up regulation and taking steps toward an overhaul of the agency's internal culture
You may also be interested in...
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Josh Sharfstein's departure.
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Josh Sharfstein's departure.
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Josh Sharfstein's departure.